- Horizon Pharma (HZNP) acquires Vidara Therapeutics in a cash-and-stock reverse merger valued at $660M.
- 74% of Horizon Pharma plc (the new company name) ordinary shares will be exchanged for Horizon Pharma Inc.'s common shares. Vidara will receive 26% of Horizon Pharma plc plus $200M cash.
- Expected pro forma revenues for 2014 are $250M - $265M.
- Timothy P. Walbert, Horizon Pharma Inc. Chairman, President and CEO will lead the new entity.